Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pelacarsen - Novartis

Next Previous
Drug Profile

Pelacarsen - Novartis

Alternative Names: AKCEA-APO(a)-LRx; IONIS-681257; IONIS-APO(a)-LRx; IONIS-APO-LRx; ISIS-681257; ISIS-APO(a)-LRx; ISIS-APOALRx; Pelacarsen sodium; TQJ 230

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Novartis
  • Class Amides; Amino sugars; Antihyperlipidaemics; Antisense oligonucleotides; Drug conjugates; Vascular disorder therapies
  • Mechanism of Action Apolipoproteins A expression inhibitors; Gene silencing; Lipoprotein A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atherosclerosis; Hyperlipoproteinaemia

Most Recent Events

  • 03 Jun 2025 Clinical trials in Atherosclerosis (SC) (NCT07000695)
  • 19 May 2025 Phase-III clinical trials in Atherosclerosis in USA (SC) (NCT06875973)
  • 30 Apr 2025 Novartis Pharmaceuticals initiates a phase III (ADD-VANTAGE) trial for Hyperlipoproteinaemia (SC, injection) in USA (NCT06813911)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top